排序方式: 共有65条查询结果,搜索用时 62 毫秒
1.
The purpose of the present study was to evaluate aceclofenac eye drop through excised goat cornea. Raising pH of the formulation from 6.0 to 8.0, effect of different preservatives or effect of viscosity enhancer decreases apparent permeability coefficient. Topical ophthalmic NSAID are used to treat ocular surface and anterior segment inflammation as well as post operative management of pain and inflammation. Aceclofenac’s unique chemical structure makes it both a potent anti inflammatory drug and lipophilic molecule that penetrates ocular tissue, ensuring relief of pain in cataract and refractive surgery and corneal abrasion. The octanol/water partition coefficient of aceclofenac drug is 1.86 ± 0.75. Permeation characteristics of the drug were evaluated by putting 1 ml formulation on freshly excised goat cornea fixed between donor and receptor compartments of an all-glass modified Franz diffusion cell and measuring the drug permeated in the receptor by spectrophotometry at 275 nm, after 120 min. The results suggest that aceclofenac ophthalmic solution (pH 7) containing BAC provides increased in vitro ocular availability through goat corneas. The combination of methyl paraben and propyl paraben MP–PP preservative in aceclofenac ophthalmic eye drop 0.1% formulated in phosphate buffer increases transcorneal permeation. The developed formulations were evaluated for their pharmacodynamics in albino rabbits, by measuring in-vivo study and were compared to a marketed voltrane ophthalmic solution. 相似文献
2.
《Journal of microencapsulation》2013,30(8):794-803
AbstractContext: Rheumatoid arthritis (RA) is differentiated as an early morning exacerbation of the core arthritis condition associated with increase in pain and stiffness in joints and necessitate for medication. Objective: The aim of the present work was to develop and optimise a pH-triggered delayed-release colon-specific aceclofenac microspheres and to accomplish chronotherapy of RA. Methods: A 3-factor, 3-level Box–Behnken design (BBD) was used to optimise selected variables. Developed formulation was evaluated for in vivo delayed response and anti-arthritis activity in rats. Results: The particle size and encapsulation efficacy of these microspheres were 117.36?±?10.54?µm and 85.06?±?5.85%, respectively. Optimised formulation was analysed by SEM, DSC, X-RPD and FTIR. The in vivo evaluation reveled delayed anti-inflammatory activity in carrageenan-induced rats and anti-arthritic activity in freund’s adjuvant-induced arthritis rats. Conclusion: The optimised aceclofenac microspheres formulation is potential for the chronotherapy of early morning symptoms of RA. 相似文献
3.
To develop novel transdermal formulation for aceclofenac, microemulsion was prepared for increasing its skin permeability. Based on solubility and phase studies, oil and surfactant was selected and composition was determined. Microemulsion was spontaneously prepared by mixing ingredients and the physicochemical properties such was investigated. The mean diameters of microemulsion were approximately 90 nm and the system was physically stable at room temperature at least for 3 months. In addition, the in vitro and in vivo performance of microemulsion formulation was evaluated. Aceclofenac was released from microemulsion in acidic aqueous medium, and dissolved amounts of aceclofenac was approximately 30% after 240 min. Skin permeation of aceclofenac from microemulsion formulation was higher than that of cream. Following transdermal application of aceclofenac preparation to delayed onset muscle soreness, serum creatine phosphokinase and lactate dehydrogenase activity was significantly reduced by aceclofenac. Aceclofenac in microemulsion was more potent than cream in the alleviation of muscle pain. Therefore, the microemulsion formulation of aceclofenac appear to be a reasonable transdermal delivery system of the drug with enhanced skin permeability and efficacy for the treatment of muscle damage. 相似文献
4.
目的研究醋氨芬酸肠溶片的人体药代动力学。方法12名健康男性志愿者口服国产醋氯芬酸肠溶片100mg,采用HPLC法测定给药后不同时间点的血浆醋氮芬酸浓度。用DAS程序计算其药代动力学参数。结果健康志愿者单剂量口服醋氯芬酸肠溶片后,血浆的醋氯芬酸Cmax为(9.13±3.73)mg/1.;Tmax为(2.27±0.88)h;t1/2(ke)为(2.54±1.35)h;CL为(1.96±0.79)L/h;Vd为(6.50±3.16)L;AUC为(54.40±20.22)mg·h/L。结论单剂量口服国产醋氮芬酸肠溶片,其人体药代动力学符合一级吸收的一室模型。 相似文献
5.
Summary A multicentre randomised, double-blind, parallel group, general practice study was undertaken to investigate the efficacy and safety of aceclofenac (200 patients, 100mg twice daily and placebo once daily) in comparison with diclofenac (197 patients, 50mg three times daily) in patients with osteoarthritis of the knee. The treatment period of twelve weeks was preceded by a washout period of two weeks duration. At end point, patients in both aceclofenac and diclofenactreated groups exhibited significant improvement in pain intensity (p=0.0001). Although both treatment groups showed significant improvement in all investigators' clinical assessments (joint tenderness, swelling, pain on movement, functional capacity, overall assessment), there were no significant differences between the groups. There was, however, a trend towards greater improvement in complete knee movement and reduced pain on movement with aceclofenac. In patients with initial flexion deformity, aceclofenac was significantly more effective than diclofenac in improving knee flexion after 2–4 weeks of treatment. Patients' subjective assessment of pain relief demonstrated significantly greater efficacy with aceclofenac. At end point, 71% of patients in the aceclofenac group reported improvement in pain intensity as compared to 59% treated with diclofenac (p=0.005). Tolerability of aceclofenac was better than with diclofenac as fewer patients experienced gastrointestinal adverse events. In particular, the incidence of treatment related diarrhoea was less with aceclofenac (1%) than with diclofenac (6.6%). In summary, this study supports a therapeutic role for aceclofenac in arthritis and suggests that it is an alternative NSAID to diclofenac in the treatment of osteoarthritis. 相似文献
6.
The efficacy and tolerability of aceclofenac, a new non-steroidal anti-inflammatory drug (NSAID) was compared to that of ketoprofen in a multicentre, double-blind, prospective, randomized study of 3-months duration in patients with rheumatoid arthritis. One hundred and sixty-nine patients, aged between 22 and 70 years, were included in the study. Patients were randomly assigned to two treatment groups; either aceclofenac 100 mg b.i.d. (87 patients) or ketoprofen 50 mg t.i.d. (82 patients). A placebo tablet was administered to aceclofenac-treated patients to maintain the double-blind conditions of the study. Patients were examined at 15 days and at 1,2 and 3 months. Efficacy was assessed by the following clinical parameters: Ritchie index, pain on a visual analogue scale, grip strength, morning stiffness, spontaneous morning pain, pain on movement and nocturnal pain, together with functional capacity. Efficacy was demonstrated for both drugs, with progressive improvement in the main clinical evaluation parameters until the end of the treatment period. This was particularly pronounced at 15 days in the aceclofenac group, with a rapid improvement in the Ritchie index (base-line vs 15 days: P<0.001). Laboratory analyses performed were all within the normal range for both drugs. Eleven patients in the ketoprofen group abandoned the study because of inefficacy, whilst only 4 patients discontinued the treatment for this reason in the aceclofenac group. Eleven patients in the ketoprofen group and 2 patients in the aceclofenac group withdrew from the study because of adverse events. In summary, this study demonstrated that aceclofenac, a new NSAID, is effective in the symptomatic treatment of RA with a minor number of patient withdrawals because of inefficacy and a better safety profile than ketoprofen.Preliminary results from this study have been published in Rev Esp Reumatol 1992; 19:263–268 相似文献
7.
采用HPLC法研究醋氯芬酸在大鼠体内的药代动力学。醋氯芬酸在大鼠体内的吸收较为迅速,给药后约10min达到血药浓度峰值,其药-时曲线符合一级吸收的二室模型,分布半衰期仅为4min左右,消除半衰期约为50min。三种剂量下的AUC分别为42.1、90.3、181.8μgmin/ml,剂量与AUC具有良好的线性关系,提示醋氯芬酸在大鼠体内的处置属于线性动力学,其动力学参数呈剂量非依赖性。大鼠按10mg/kg剂量灌服醋氯芬酸后,心、胃、肠和肌肉组织内的浓度较高。醋氯芬酸在大鼠粪、尿和胆汁中的排泄较少。大鼠按10mg/kg剂量灌服醋氯芬酸后,其24h内累积尿排泄百分率仅为0.090%±0.018%;其24h内累积粪便排泄百分率仅为0.22%±0.07%;其12h内累积胆汁排泄百分率仅为0.33%±0.09%。 相似文献
8.
The aim of present study was to prepare and characterized ethosomes of aceclofenac which may deliver the drug to targeted site more efficiently than marketed gel preparation and also overcome the problems related with oral administration of drug. The formulations were prepared with varying the quantity of ethanol 10-50% (v/v), lecithin 1-4% (w/v), propylene glycol 5-20% (v/v) and evaluated for their vesicle size, shape and surface morphology, entrapment efficiency and in vitro drug permeation study. Ethosomes of average size of 1.112 μm with a spherical shape bearing smooth surface were observed by transmission electron microscopy and surface electron microscopy. The maximum entrapment of ethosomes was 91.06±0.79%. Cumulative amount of drug permeated through the biological membrane was found to be in the range of 0.26±0.014 to 0.49±0.032 mg/cm(2). Stability profile of prepared system was assessed for 45 days and the results revealed that very less degradation of drug was observed during storage condition. 相似文献
9.
《Current medical research and opinion》2013,29(5):977-988
ABSTRACTObjective: Osteoarthritis is one of the most common forms of arthritis seen in primary care. Non-steroidal anti-inflammatory drugs (NSAIDs) play an important role in the management of osteoarthritis. However, gastrointestinal (GI) side effects limit their use. Cyclooxygenase-2 (COX‐2) selective inhibitors exhibit better GI tolerability than conventional NSAIDs, but their cardiovascular safety is controversial. An NSAID with high efficacy, high GI tolerability and devoid of adverse cardiovascular effects is therefore a profile preferred by physicians. Aceclofenac is an anti-inflammatory and analgesic drug with preferential COX-2 inhibition. The objective of this study was to assess the efficacy and safety of aceclofenac in the treatment of osteoarthritis in an Indian population.Research design and methods: The trial was controlled, comparative, randomized, and double-blind. The study included 247 patients (82 males and 165 females, 40–82 years), suffering from osteoarthritis. Patients were randomized to receive either aceclofenac (100?mg twice daily) or diclofenac (75?mg twice daily).Main outcome measures: Clinical assessment was done at screening, randomization, and at 2 weeks, 4 weeks and 8 weeks of treatment by calculating Western Ontario MacMaster (WOMAC) scores, time taken to walk 100 feet, visual analogue scores for pain, investigator's assessment on a Likert scale and joint tenderness. Tolerability assessment was based on adverse events. Patient compliance was also assessed.Results: Aceclofenac was found to be statistically superior to diclofenac in efficacy parameters of WOMAC scores, investigator's assessment and joint tenderness. Aceclofenac was found to be statistically superior to diclofenac in terms of epigastric discomfort, dyspepsia and abdominal pain. Compliance was also better with aceclofenac. The overall response of patients’ osteoarthritis to aceclofenac was found to be statistically superior to diclofenac by both physician and patient.Conclusions: Aceclofenac is an effective and well-tolerated drug in osteoarthritis in the Indian setting. 相似文献
10.
Maha Nasr Samar Mansour Nahed D. Mortada A. A. Elshamy 《Journal of microencapsulation》2013,30(7):499-512
Vesicular delivery systems have been reported to serve as local depot for sustained drug release. Aceclofenac multilamellar liposomes and niosomes were prepared and a comparative study was done between them through evaluation of entrapment efficiency, particle size, shape, differential scanning calorimetry and in vitro drug release. A stability study was carried out by investigating the leakage of aceclofenac and the change in the vesicles particle size when stored at (2–8°C) for 3 months. The anti-inflammatory effect of aceclofenac vesicles was assessed by the rat paw oedema technique. Results showed that the entrapment efficiency and the in vitro release of aceclofenac from the vesicles can be manipulated by varying the cholesterol content, the type of surfactant as well as the type of charge. Niosomes showed better stability than liposomes. Both vesicular systems showed significant sustained anti-inflammatory activity compared to the marketed product, with niosomes being superior to liposomes as manifested by both oedema rate and inhibition rate percentages suggesting their effectiveness as topical anti-inflammatory delivery systems. 相似文献